For the quarter ending 2026-03-31, EDSA has $12,384,738 in assets.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 10,003,683 | 12,051,748 | 10,792,172 | 12,361,690 |
| Accounts and other receivable | 216,468 | 431,325 | 642,866 | 286,743 |
| Prepaid expenses and other current assets | 197,576 | 234,414 | 77,838 | 112,659 |
| Total current assets | 10,417,727 | 12,717,487 | 11,512,876 | 12,761,092 |
| Right-of-use assets | - | - | 0 | 0 |
| Long-term deposits | 39,921 | 40,572 | 39,966 | 40,739 |
| Intangible asset, net | 1,927,090 | 1,952,383 | 1,977,676 | 2,002,969 |
| Total assets | 12,384,738 | 14,710,442 | 13,530,518 | 14,804,800 |
| Short-term right-of-use lease liabilities | - | - | 0 | 0 |
| Accounts payable and accrued liabilities | 2,187,921 | 756,163 | 1,078,536 | 672,674 |
| Total current liabilities | 2,187,921 | 756,163 | 1,078,536 | 672,674 |
| Authorized unlimited common shares without par value issued and outstanding 8,885,719 common shares (september 30, 2025 -7,141,783) | 58,932,825 | 57,899,593 | 54,515,421 | 54,271,112 |
| Preferred stock, shares issued-Series A1Preferred Stock | 1,166,517 | 1,129,530 | 1,092,133 | 1,054,735 |
| Preferred stock, shares issued-Series B1Preferred Stock | 7,208,266 | 8,168,063 | 8,168,063 | 8,168,063 |
| Additional paid-in capital | 15,526,657 | 15,124,219 | 14,753,110 | 14,406,511 |
| Accumulated other comprehensive loss | -186,089 | -171,086 | -165,771 | -123,077 |
| Accumulated deficit | -72,451,359 | -68,196,040 | -65,910,974 | -63,645,218 |
| Total shareholders' equity | 10,196,817 | 13,954,279 | 12,451,982 | 14,132,126 |
| Total liabilities and shareholders' equity | 12,384,738 | 14,710,442 | 13,530,518 | 14,804,800 |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)